GMED

$88.16

Market ClosedAs of Mar 17, 8:00 PM UTC

Globus Medical, Inc.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$88.16
Potential Downside
9%
Whystock Fair Value$80.20
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle scre...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$11.92B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
22.49
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.07
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
12.29%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
2.61

Recent News

StockStory
Mar 17, 2026

1 Cash-Producing Stock to Target This Week and 2 That Underwhelm

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 17, 2026

Should You Continue to Hold Bio-Techne Stock in Your Portfolio?

TECH expands via acquisitions and global growth, but biotech funding softness, U.S. academic spending pressure and competition cloud near-term outlook.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Mar 17, 2026

Is Resmed Stock the Right Pick for Your Portfolio Now?

RMD expands mask and device sales while maintaining strong liquidity, but macro and competitive pressures loom.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Mar 16, 2026

Should You Continue to Hold Integra Stock in Your Portfolio Now?

IART faces macro headwinds and tight liquidity, but strong demand in its Codman Specialty Surgical unit and expanding international launches could support growth.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 13, 2026

Reasons to Hold Tandem Diabetes Stock in Your Portfolio for Now

New pump launches, CGM integrations and strong solvency support Tandem Diabetes' growth outlook, though intense competition and macro headwinds remain risks.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.